Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Foot Ulcer (DFU) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Symptoms 9
2.5 Diagnosis 10
2.5.1 History and Physical Examination 10
2.5.2 Laboratory Tests 10
2.6 Treatment and Management Pattern 10
2.6.1 Management of Co-morbidities 10
2.6.2 Evaluation of Vascular Status 10
2.6.3 Tissue Management 11
2.7 GlobalData Pipeline Report Guidance 12
3 DFU Therapeutics: Market Characterization 13
3.1 DFU Therapeutics Global Market Size 13
3.2 DFU Therapeutics Market Forecast 15
3.3 DFU Therapeutics Market Size – The US (2005-2010) 17
3.4 DFU Therapeutics Market Forecast – The US (2010-2017) 19
3.5 DFU Therapeutics Market Size – France (2005-2010) 21
3.6 DFU Therapeutics Market Forecast – France (2010-2017) 23
3.7 DFU Therapeutics Market Size – Germany (2005-2010) 25
3.8 DFU Therapeutics Market Forecast – Germany (2010-2017) 27
3.9 DFU Therapeutics Market Size - Italy (2005-2010) 29
3.10 DFU Therapeutics Market Forecast - Italy (2010-2017) 31
3.11 DFU Therapeutics Market Size – Spain (2005-2010) 33
3.12 DFU Therapeutics Market Forecast – Spain (2010-2017) 35
3.13 DFU Therapeutics Market Size – The UK (2005-2010) 37
3.14 DFU Therapeutics Market Forecast – The UK (2010-2017) 39
3.15 DFU Therapeutics Market Size - Japan (2005-2010) 41
3.16 DFU Therapeutics Market Forecast – Japan (2010-2017) 43
3.17 Drivers and Restraints for the DFU Therapeutics Market 45
3.17.1 Drivers of the DFU Therapeutics Market 45
3.17.2 Barriers for DFU Therapeutics Market 45
3.18 Opportunity and Unmet Need Analysis 46
3.19 Key Takeaway 46
4 DFU Therapeutics: Competitive Assessment 47
4.1 Overview 47
4.2 Strategic Competitor Assessment 47
4.3 Major Marketed Product Profiles in DFU Therapeutics Market 48
4.3.1 Invanz (ertapenam) 48
4.3.2 Regranex (becaplermin) 49
4.3.3 Zyvox (linezolid) 50
4.3.4 Zosyn (piperacillin/tazobactam) 51
4.4 Key Takeaway 52
5 DFU Therapeutics: Pipeline Assessment 53
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.2.1 Technology Trends Analytic Framework 53
5.3 DFU Therapeutics – Pipeline by Phases of Development 54
5.3.1 DFU Therapeutics – Phase III Pipeline 54
5.3.2 DFU Therapeutics – Phase II Pipeline 55
5.3.3 DFU Therapeutics – Phase I Pipeline 55
5.3.4 DFU Therapeutics – Preclinical/ Discovery Clinical Pipeline 55
5.4 DFU Therapeutics – Pipeline by Mechanism of Action 56
5.5 Technology Trends Analytic Framework 57
5.6 DFU Therapeutics– Most Promising Drugs under Clinical Development 58
5.7 Most Promising Drugs Profile 59
5.7.1 Pexiganan (pexiganan acetate) 59
5.7.2 Fragmin (Dalteparin Sodium) 59
5.7.3 CVBT-141B (FGF-1) 60
5.8 Key Takeaway 61
6 DFU Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 66
7 DFU Therapeutics: Strategic Assessment 68
7.1 Key Events impacting the Future Market 68
7.2 Future Market Competition Scenario 68
8 DFU Therapeutics: Future Players 70
8.1 Introduction 70
8.2 Company Profiles 70
8.2.1 Pfizer Inc. 70
8.2.2 Genaera Corporation 74
8.2.3 Cardiovascular Biotherapeutics, Inc 75
8.2.4 Tabular Presentation Details of Other Companies in the Pipeline 76
9 DFU Therapeutics: Licensing & Partnership Deals 82
10 DFU Therapeutics: Appendix 84
10.1 Definitions 84
10.2 Acronyms 84
10.3 Research Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Forecasting 86
10.3.4 Primary Research 89
10.3.5 Expert Panels 89
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Bibliography 90
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Foot Ulcer (DFU) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Symptoms 9
2.5 Diagnosis 10
2.5.1 History and Physical Examination 10
2.5.2 Laboratory Tests 10
2.6 Treatment and Management Pattern 10
2.6.1 Management of Co-morbidities 10
2.6.2 Evaluation of Vascular Status 10
2.6.3 Tissue Management 11
2.7 GlobalData Pipeline Report Guidance 12
3 DFU Therapeutics: Market Characterization 13
3.1 DFU Therapeutics Global Market Size 13
3.2 DFU Therapeutics Market Forecast 15
3.3 DFU Therapeutics Market Size – The US (2005-2010) 17
3.4 DFU Therapeutics Market Forecast – The US (2010-2017) 19
3.5 DFU Therapeutics Market Size – France (2005-2010) 21
3.6 DFU Therapeutics Market Forecast – France (2010-2017) 23
3.7 DFU Therapeutics Market Size – Germany (2005-2010) 25
3.8 DFU Therapeutics Market Forecast – Germany (2010-2017) 27
3.9 DFU Therapeutics Market Size - Italy (2005-2010) 29
3.10 DFU Therapeutics Market Forecast - Italy (2010-2017) 31
3.11 DFU Therapeutics Market Size – Spain (2005-2010) 33
3.12 DFU Therapeutics Market Forecast – Spain (2010-2017) 35
3.13 DFU Therapeutics Market Size – The UK (2005-2010) 37
3.14 DFU Therapeutics Market Forecast – The UK (2010-2017) 39
3.15 DFU Therapeutics Market Size - Japan (2005-2010) 41
3.16 DFU Therapeutics Market Forecast – Japan (2010-2017) 43
3.17 Drivers and Restraints for the DFU Therapeutics Market 45
3.17.1 Drivers of the DFU Therapeutics Market 45
3.17.2 Barriers for DFU Therapeutics Market 45
3.18 Opportunity and Unmet Need Analysis 46
3.19 Key Takeaway 46
4 DFU Therapeutics: Competitive Assessment 47
4.1 Overview 47
4.2 Strategic Competitor Assessment 47
4.3 Major Marketed Product Profiles in DFU Therapeutics Market 48
4.3.1 Invanz (ertapenam) 48
4.3.2 Regranex (becaplermin) 49
4.3.3 Zyvox (linezolid) 50
4.3.4 Zosyn (piperacillin/tazobactam) 51
4.4 Key Takeaway 52
5 DFU Therapeutics: Pipeline Assessment 53
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.2.1 Technology Trends Analytic Framework 53
5.3 DFU Therapeutics – Pipeline by Phases of Development 54
5.3.1 DFU Therapeutics – Phase III Pipeline 54
5.3.2 DFU Therapeutics – Phase II Pipeline 55
5.3.3 DFU Therapeutics – Phase I Pipeline 55
5.3.4 DFU Therapeutics – Preclinical/ Discovery Clinical Pipeline 55
5.4 DFU Therapeutics – Pipeline by Mechanism of Action 56
5.5 Technology Trends Analytic Framework 57
5.6 DFU Therapeutics– Most Promising Drugs under Clinical Development 58
5.7 Most Promising Drugs Profile 59
5.7.1 Pexiganan (pexiganan acetate) 59
5.7.2 Fragmin (Dalteparin Sodium) 59
5.7.3 CVBT-141B (FGF-1) 60
5.8 Key Takeaway 61
6 DFU Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 66
7 DFU Therapeutics: Strategic Assessment 68
7.1 Key Events impacting the Future Market 68
7.2 Future Market Competition Scenario 68
8 DFU Therapeutics: Future Players 70
8.1 Introduction 70
8.2 Company Profiles 70
8.2.1 Pfizer Inc. 70
8.2.2 Genaera Corporation 74
8.2.3 Cardiovascular Biotherapeutics, Inc 75
8.2.4 Tabular Presentation Details of Other Companies in the Pipeline 76
9 DFU Therapeutics: Licensing & Partnership Deals 82
10 DFU Therapeutics: Appendix 84
10.1 Definitions 84
10.2 Acronyms 84
10.3 Research Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Forecasting 86
10.3.4 Primary Research 89
10.3.5 Expert Panels 89
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Bibliography 90
...